focus -WSS

focus

author：explore 2025-09-27 12:47:44 - browse：77579

In 2018, New York University became the first U.S. medical school to go tuition free. Since then, a handful of others have followed with many more considering similar programs. One hope for free tuition endeavors is that lower post-graduation debt will increase the number of med students who choose lower-paying, desperately needed careers in primary care and pediatrics. But free tuition programs are not necessarily delivering on that promise.

In this episode of the First Opinion Podcast, University of Pennsylvania oncologist and researcher Ezekiel Emanuel and Matthew Guido, a project manager in the Healthcare Transformation Institute, discuss their original research on tuition-free programs with former host Pat Skerrett, who is filling in while Torie Bosch is on maternity leave. They make the case that medical school debt is only one of many factors that influence new doctors to choose less-popular specialties and geographic locations for their residencies. Other factors including prestige, the lifetime earning potential of higher-pay specialties, which can add several millions dollars over a career, can have more sway than student debt alone. This is especially important, they say, as needs for patients with chronic illnesses are rapidly outpacing the number of primary care physicians available to give that care.

“We have undervalued both philosophically and also financially the complications of managing chronic illness,” Emanuel says. “Can we rebalance the payment system that rewards the improvements in health and therefore the attention to chronic illness through primary care?”

You can read more about Emanuel and Guido’s opinions in their essay “Free med school tuition won’t solve the shortage of primary care physicians.”

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Spotify, Google Play, or wherever you get your podcasts. And don’t forget to sign up for the First Opinion newsletter to read each week’s best First Opinion essays.

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Senators: Long

WSS

Timeline: Key moments in fight for gay rights

Pioneering cancer drug will cost $475,000. Analysts call it a bargain

Changes to biosimilar regulatory framework must prioritize patients

How AI helped researchers track recovery from depression

The thinking behind the controversial eating disorder chatbot Tessa

Living organ donors deserve priority status for transplants

knowledge

focus

focus

The cancer drug shortage isn’t new — and neither are the solutions

Ukraine and a new approach to mental health in war

Jerome Adams on the need for new antivirals for Covid

We're not in Australia anymore: Kansas cops jump into action to save kangaroo

The high cost of giving birth even with insurance

Ukraine and a new approach to mental health in war

Alkermes shareholders re

CommonSpirit Health keeps growing, even as it loses money

Dobbs anniversary: the lost opportunity of abortion as health care

FDA approves first new drug developed for postpartum depression

focus

FDA approves first new drug developed for postpartum depression

Thermo Fisher plant for manufacturing gene therapies to expand

CDC advisers recommend seasonal use of Pfizer RSV shot

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

Eli Lilly’s Mounjaro succeeds in second weight

Living organ donors deserve priority status for transplants

hotspot

focus

focus

hotspot